Max Macaluso
TMFMassimo
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Recent Articles by Max Macaluso

Apr 7, 2017
by Max Macaluso
Why Investors Don’t Care About This Sarepta News

Apr 7, 2017
by Max Macaluso
Why Doesn’t MannKind Have a Partner?

Apr 7, 2017
by Max Macaluso
Will This Stock MAKO or Break-O Your Portfolio?

Apr 7, 2017
by Max Macaluso
1 Catalyst to Watch at OraSure Technologies

Apr 7, 2017
by Max Macaluso
Should Investors Be Angry With Big Pharma?

Apr 7, 2017
by Max Macaluso
Science That VIVUS Investors Need to Know

Apr 7, 2017
by Max Macaluso
1 Amarin Catalyst to Watch

Apr 7, 2017
by Max Macaluso
Science Arena Investors Need to Know

Apr 7, 2017
by Max Macaluso
Could Amarin Be an Acquisition Target?

Apr 7, 2017
by Max Macaluso
Don't Be Fooled By This Dow Impostor

Apr 7, 2017
by Max Macaluso
Should This News Scare Amarin Investors?

Apr 7, 2017
by Max Macaluso
Why Zalicus and Geron Shares Plunged

Apr 7, 2017
by Max Macaluso
1 Emerging-Market Threat to Big Pharma

Apr 7, 2017
by Max Macaluso
3 Things to Watch in the Video-Game Sector
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.